Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRDL with free AI briefings, catalyst countdowns, and dilution alerts.

CRDL · Cardiol Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$26.1M Cash on Hand
13mo Cash Runway
2.2% Short Interest
$8.41 Analyst Target (5)
Follow CRDL by email Get an email when CRDL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRDL, unsubscribe in one click. Privacy

📣 What CRDL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CardiolRx Recurrent Pericarditis Phase 3 · NCT06708299 Recruiting

Also used in these trials (approved or third-party drugs, not CRDL's own candidates): Cannabidiol.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRDL holds $26.1M in cash and short-term investments and burns about $6M/quarter from operations, an estimated runway of 13 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRDL files for a raise →

👥 Who Owns CRDL

Insiders Form 4 data not loaded yet Institutions 42.6% Public and other holders 57.4%
HolderTypeShares% of sharesAs of
MMCAP International Inc. SPC Institution (13G, 5%+) 21,310,099 21.26% 2026-06-30
Tejara Capital Ltd Institution (13G, 5%+) 6,382,551 6.37% 2026-09-02
Ikarian Capital, LLC Institution (13F) 3,325,000 3.32% 2026-09-30
Ameriprise Financial, Inc. Institution (13F) 2,246,787 2.24% 2026-09-30
Woodline Partners LP Institution (13F) 2,226,653 2.22% 2026-09-30
J. Goldman & Co., L.P. Institution (13F) 1,942,557 1.94% 2026-09-30
Point72 Asset Management, L.P. Institution (13F) 1,740,891 1.74% 2026-09-30
Two Sigma Investments, LP Institution (13F) 1,091,646 1.09% 2026-09-30
Morgan Stanley Institution (13F) 1,010,687 1.01% 2026-09-30
Boothbay Fund Management, LLC Institution (13F) 975,721 0.97% 2026-09-30
Integrity Alliance, Llc. Institution (13F) 310,896 0.31% 2026-09-30
Jane Street Group, LLC Institution (13F) 152,876 0.15% 2026-09-30

Share count 100,257,009 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRDL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRDL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.